Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 212

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 6
Chunk 212
---
 and was appointed to the Leadership Team in January 2023. Claire de Saint-Blanquat has more than 20 years of experience in diverse legal positions in the pharmaceutical industry. Admitted to the Paris Bar in 1998, she started her career at Clifford Chance and then held senior positions, notably at Teva, Servier and Biogaran, where she was Legal and Compliance Director since 2016. Claire de Saint-Blanquat holds a master's degree in private law from the University of Paris II - Panthéon Assas (1995), a DEA in civil and commercial obligations law from the University of Paris V - Malakoff (1996) and a DESS in biotechnology law from the University of Versailles- Saint Quentin (2003).

Henry Wheeler, MSc, member of the Leadership Team, Investor Relations and Communications, joined Innate Pharma as Vice President, Investor Relations in June 2021 and was appointed to the Leadership Team in January 2023. Henry Wheeler has over 15 years’ experience across the pharmaceutical and financial industries. Henry Wheeler joined from AstraZeneca, where he led investor relations for the company’s oncology portfolio, having previously served within AstraZeneca’s Oncology Business Unit. Prior to this, Henry Wheeler worked in various healthcare financial roles, including at Third Bridge and Morgan Stanley in London. Henry Wheeler graduated with a MSc in Drug Discovery Skills and a BSc with honors in Pharmacology, both from King's College, London.

Hervé Brailly, Innate Pharma’s former CEO and co-founder was appointed as interim CEO and Chairman of the Executive Board from January 1, 2024 to October 31, 2024. Jonathan Dickinson was appointed as Chairman of the Executive Board effective November 1, 2024.

On January 4, 2024, Innate Pharma announced that it appointed two new Executive Board members. Arvind Sood, Executive Vice President, President of U. S. Operations, and Sonia Quaratino, Executive Vice President, Chief Medical Officer have joined Hervé Brailly, interim Chief Executive Officer and Yannis Morel, Executive Vice President, Chief Operating Officer.

Yannis Morel, current Executive Vice President, Business Development and Product Portfolio Strategy, member of the Executive Board and member of the Leadership Team broadened his remit to become Executive Vice President, Chief Operating Officer extending his operational responsibility to the management of research and early development, working with Innate Pharma